• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

  • — 10 Dec, 2007
AudioMedica News
AudioMedica News
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
00:00 /
RSS Feed
Share
Link
Embed
Pierre Fenaux
Pierre Fenaux

PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University gave the details to Derek Thorne.

Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes
[audio:https://www.audiomedica.com/podcasting/oncology/071209_pierre_fenaux.mp3]

You may also like...

  • Ian Kunkler Stage I to III breast cancer: radiation therapy to chest lymph nodes extends life 26 Oct, 2013
  • Interval Breast Lumps signal cancer risk Breast Lumps Between Mammography Visits Signal High Risk 19 Apr, 2018
  • Bevacizumab: New Standard for Non-Small Cell Lung Cancer? Bevacizumab: New Standard for Non-Small Cell Lung Cancer? 16 Mar, 2008
  • Gastrointestinal Cancers: Progress with Targeted Therapies Gastrointestinal Cancers: Progress with Targeted Therapies 27 Jan, 2008
  • Previous story Live Report from ASH:
    Interleukin-2 For Acute Myeloid Leukemia In First Remission?
  • Next story Live Report from ASH:
    Dasatinib Effective At Two Years’ Follow Up in Chronic Phase CML
  • News

    • Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”Liquid Biopsy ctDNA Prediction of Lung Cancer Relapse “Ready for Prime Time”August 4, 2022
    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic Lymphocytic…
    • Microbiome Diversity Key To Survival After Allogeneic…
    • New Front Line Standard for Older Patients with Chronic…
    • Which Tasks Most Influence Pediatric PT Productivity,…
    • Genomic-led AML Clinical Decision Making Within Seven Days
  • Home
  • Oncology
  • Live Report from ASH: Azacitidine ‘New Standard’ In High Risk Myelodysplastic Syndromes

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.